- October 17, 2008
- CeNeRx BioPharma initiates Phase 2 clinical trial of its novel antidepressant agent Tyrima™
- October 17, 2008
- CeNeRx BioPharma completes $15 Million Series B financing
- September 23, 2008
- Anthera completes special protocol assessment with FDA and receives EMEA scientific advice on development path toward varespladib approval
- September 5, 2008
- CoLucid presents Phase 2 results of COL-144 at European Headache and Migraine Trust International Congress 2008
- September 3, 2008
- Plexxikon initiates Phase 1 Trial for PLX5568
- August 25, 2008
- Anthera advances global development strategy for varespladib with the initiation of FRANCIS trial
- July 22, 2008
- CeNeRx BioPharma to initiate Phase 2 trials for its novel antidepressant agent Tyrima™ using innovative brain imaging study
- July 1, 2008
- CoLucid announces $25 million Series B financing for advancement of first-in-class migraine compound
- June 25, 2008
- Methylgene announces the initiation of a Phase 2 trial of MGCD0103
- May 21, 2008
- Plexxikon announces preclinical data demonstrating dramatic improvement in key symptoms of polycystic kidney disease
- May 20, 2008
- Dynogen presents results of its positive Phase 2 IBS-d study with DDP225
- April 30, 2008
- Genstruct and Sirtris Pharmaceuticals win Bio-IT World's Best Practices Award
- April 17, 2008
- BrainCells expands Series B financing to $50 million
- April 17, 2008
- BrainCells Inc. initiates Phase 2 clinical trial with BCI-540 for depression with anxiety
- April 16, 2008
- MethylGene initiates Phase 1 clinical trial for its multi-targeted (c-Met) kinase inhibitor, MGCD265, in solid tumor cancers
- April 16, 2008
- Bayhill Therapeutics presents data from a Phase 2 trial of BHT-3009 in multiple sclerosis at American Academy of Neurology 60th annual meeting
- April 16, 2008
- DSMB supports continuation of Anthera Phase 2 impacts trial for the prevention of acute chest syndrome in patients with sickle cell disease
- April 7, 2008
- UCSD, TargeGen team-up on blood disease treatment
- March 27, 2008
- LipoScience: LDL particle measurement by NMR recognized in consensus statement by the ADA and the ACC
- March 19, 2008
- Genstruct: Patience, Persistence, and Payoff
- March 17, 2008
- BioSyntech announces positive preliminary interim data for BST-CarGel® clinical trial
- March 4, 2008
- Biovitrum and Syntonix set to begin Phase 1/2a clinical trial for the treatment of Hemophilia B
- February 28, 2008
- TyRx Pharma raises $25 million
- February 27, 2008
- Athersys announces summary results for Phase 1 safety study of its novel obesity drug
- February 20, 2008
- Genstruct announces new collaboration with Pfizer in drug safety
- February 14, 2008
- MethylGene and Pharmion announce orphan drug designation for treatment of acute myelogenous leukemia
- February 6, 2008
- Apex Bioventures and Dynogen Pharmaceuticals announce definitive merger agreement
- January 31, 2008
- TargeGen announces initiation of clinical trial of JAK2 inhibitor TG101348 in myeloproliferative disease patients
- January 31, 2008
- Anthera enters into manufacturing agreements for Varespladib in preparation for pivotal Phase 3 trials
- January 16, 2008
- Dynogen expands DDP225 patent estate
- January 15, 2008
- Anthera announces preliminary positive results from once-daily A-002 Phase 2 cardiovascular trial
- January 9, 2008
- Bayhill Therapeutics files registration statement for proposed initial public offering